Chimeric Antigen Receptors: The Future of Cancer Immunotherapy

Authors

  • Adam Eqbal
  • Ben Li

DOI:

https://doi.org/10.15173/m.v1i26.948

Abstract

Chemotherapy, radiation therapy, and surgery are currently the most widely
used cancer treatment modalities. Although these therapies have successfully
been used to treat various cancers, they are accompanied by significant
limitations. Cancer immunotherapy, an emerging field of study named the
breakthrough of the year in 2013 is offering hope for an era of new anticancer
modalities.1 In addition to serving as a safeguard against infectious
disease, the immune system also prevents and delays tumour development..
Scientists have developed various immunotherapeutic treatments, each
targeting different aspects of the immune system. One therapy involves
genetically engineering T lymphocytes with chimeric antigen receptors (CARs)
that enhance the ability of T-cells to recognize and eliminate cancer cells. CART-
cell therapy has been highly effective in several clinical trials, eliminating
detectable tumour mass in several patients with B-cell malignancies and
solid tumours.2 This article will provide background into the field of cancer
immunotherapy, the structure and function of CARs, and recent developments
in CAR-T-cell therapy.

References

Couzin-Frankel J. Cancer Immunotherapy. Science.

Dec 20;342(6165):1432–3.

Barrett DM, Singh N, Porter DL, Grupp SA, June

CH. Chimeric Antigen Receptor Therapy for Cancer.

Annu Rev Med. 2014;65(1):333–47.

Sudhakar A. History of Cancer, Ancient and

Modern Treatment Methods. J Cancer Sci Ther.

;01(02):i–iv.

McCarthy EF. The Toxins of William B. Coley and

the Treatment of Bone and Soft-Tissue Sarcomas.

Iowa Orthop J. 2006;26:154–8.

Weiner LM, Dhodapkar MV, Ferrone S. Monoclonalantibodies for cancer immunotherapy. Lancet.

Mar 21;373(9668):1033–40.

Tagawa M. Cytokine therapy for cancer. Curr

Pharm Des. 2000 Apr;6(6):681–99.

Grupp SA, June CH. Adoptive cellular therapy.

Curr Top Microbiol Immunol. 2011;344:149–72.

Cheadle EJ, Sheard V, Hombach AA, Chmielewski

M, Riet T, Berrevoets C, et al. Chimeric antigen receptors

for T-cell based therapy. Methods Mol Biol

Clifton NJ. 2012;907:645–66.

Han EQ, Li X, Wang C, Li T, Han S. Chimeric antigen

receptor-engineered T cells for cancer immu-

Jan 15;90(2):720–4.

Penn Ovarian Cancer Research Center Immunotherapy

Program.

Sadelain M, Brentjens R, Rivière I. The Basic Principles

of Chimeric Antigen Receptor Design. Cancer

Discov. 2013 Apr 1;3(4):388–98.

Eshhar Z, Waks T, Gross G, Schindler DG.

Specific activation and targeting of cytotoxic

lymphocytes through chimeric single chains

consisting of antibody-binding domains and the

gamma or zeta subunits of the immunoglobulin

and T-cell receptors. Proc Natl Acad Sci. 1993

Dotti G, Gottschalk S, Savoldo B, Brenner

MK. Design and development of therapies

using chimeric antigen receptorexpressing

T cells. Immunol Rev. 2014

Jan;257(1):107–26.

Ahmad ZA, Yeap SK, Ali AM, Ho WY,

Alitheen NBM, Hamid M. scFv Antibody:

Principles and Clinical Application.

J Immunol Res. 2012 Mar

;2012:e980250.

Hudecek M, Lupo-Stanghellini M-T, Kosasih

PL, Sommermeyer D, Jensen MC,

Rader C, et al. Receptor Affinity and

Extracellular Domain Modifications

Affect Tumor Recognition by ROR1-

Specific Chimeric Antigen Receptor

T Cells. Clin Cancer Res. 2013 Jun

;19(12):3153–64.

Savoldo B, Ramos CA, Liu E, Mims MP,

Keating MJ, Carrum G, et al. CD28 costimulation

improves expansion and persistence

of chimeric antigen receptor–

modified T cells in lymphoma patients. J

Clin Invest. 2011 May 2;121(5):1822–

Milone MC, Fish JD, Carpenito C, Carroll

RG, Binder GK, Teachey D, et al. Chimeric

Receptors Containing CD137 Signal

Transduction Domains Mediate Enhanced

Survival of T Cells and Increased

Antileukemic Efficacy In Vivo. Mol Ther.

Apr 21;17(8):1453–64.

Zhang Q, Li H, Yang J, Li L, Zhang B, Li

J, et al. Strategies to improve the clinical

performance of chimeric antigen receptor-

modified T cells for cancer. Curr Gene

Ther. 2013 Feb;13(1):65–70.

Hennecke J, Wiley DC. T Cell Receptor–

MHC Interactions up Close. Cell. 2001

Jan 12;104(1):1–4.

Drake CG, Jaffee E, Pardoll DM. Mechanisms

of immune evasion by tumors. Adv

Immunol. 2006;90:51–81.

Bubeník J. MHC class I down-regulation:

tumour escape from immune surveillance?

(review). Int J Oncol. 2004

Aug;25(2):487–91.

Ramos CA, Dotti G. Chimeric Antigen Receptor

(CAR)-Engineered Lymphocytes

for Cancer Therapy. Expert Opin Biol Ther.

Jul;11(7):855–73.

Porter DL, Levine BL, Kalos M, Bagg A,

June CH. Chimeric antigen receptormodified

T cells in chronic lymphoid

leukemia. N Engl J Med. 2011 Aug

;365(8):725–33.

Grupp SA, Kalos M, Barrett D, Aplenc R,

Porter DL, Rheingold SR, et al. Chimeric

antigen receptor-modified T cells for

acute lymphoid leukemia. N Engl J Med.

Apr 18;368(16):1509–18.

Kochenderfer JN, Dudley ME, Kassim SH,

Somerville RPT, Carpenter RO, Stetler-

Stevenson M, et al. Chemotherapy-Refractory

Diffuse Large B-Cell Lymphoma

and Indolent B-Cell Malignancies Can Be

Effectively Treated With Autologous T

Cells Expressing an Anti-CD19 Chimeric

Antigen Receptor. J Clin Oncol. 2014 Aug

;JCO.2014.56.2025.

Maus MV, Fraietta JA, Levine BL, Kalos

M, Zhao Y, June CH. Adoptive immunotherapy

for cancer or viruses. Annu Rev

Immunol. 2014;32:189–225.

Louis CU, Savoldo B, Dotti G, Pule M,

Yvon E, Myers GD, et al. Antitumor activity

and long-term fate of chimeric antigen

receptor–positive T cells in patients

with neuroblastoma. Blood. 2011 Dec

;118(23):6050–6.

Beatty GL, Haas AR, Maus MV, Torigian

DA, Soulen MC, Plesa G, et al. Mesothelin-

Specific Chimeric Antigen Receptor

mRNA-Engineered T Cells Induce

Antitumor Activity in Solid Malignancies.

Cancer Immunol Res. 2014 Feb

;2(2):112–20.

Urruticoechea A, Alemany R, Balart J,

Villanueva A, Viñals F, Capellá G. Recent

advances in cancer therapy: an overview.

Curr Pharm Des. 2010 Jan;16(1):3–10.

Zou W. Immunosuppressive networks in

the tumour environment and their therapeutic

relevance. Nat Rev Cancer. 2005

Apr;5(4):263–74.

Chen G, Emens LA. Chemoimmunotherapy:

reengineering tumor immunity.

Cancer Immunol Immunother CII. 2013

Feb;62(2):203–16.

notherapy: progress and challenges. J Hematol

OncolJ Hematol Oncol. 2013 Jul 8;6(1):47.

Published

2014-12-21

How to Cite

1.
Eqbal A, Li B. Chimeric Antigen Receptors: The Future of Cancer Immunotherapy. M [Internet]. 2014 Dec. 21 [cited 2024 Mar. 28];1(26). Available from: https://journals.mcmaster.ca/meducator/article/view/948

Issue

Section

Critical Reviews

Most read articles by the same author(s)